Pantoprazole - CAS 102625-70-7
Catalog number: 102625-70-7
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C16H15F2N3O4S
Molecular Weight:
383.37
COA:
Inquire
Targets:
Proton Pump
Description:
Pantoprazole, an irreversible protonpump inhibitor, inhibits the final step of the production ofgastric acid by binding to the sites of H+/K+ ATPase system in gastric parietal cells.
Purity:
95%
Appearance:
Wwhite solid
Synonyms:
Pantoprazole; BY 1023; BY-1023; SK&F 96022; SK&F-96022;Protonix;102625-70-7;Pantozol;PantoprazoleSodium;Pantoprazolum
Solubility:
10 mM in DMSO
Storage:
-20ºC Freeze
MSDS:
Inquire
Application:
Pantoprazole, an irreversible protonpump inhibitor, inhibits the final step of the production ofgastric acid by binding to the sites of H+/K+ ATPase system in gastric parietal cells.
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly
Quantity:
Grams-Kilos
Boiling Point:
586.9ºC at 760 mmHg
Melting Point:
139-140ºC, decomposes
Density:
1.51 g/cm3
InChIKey:
IQPSEEYGBUAQFF-UHFFFAOYSA-N
InChI:
InChI=1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)
Canonical SMILES:
COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC
1.Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole.
Ormeci A;Emrence Z;Baran B;Gokturk S;Soyer OM;Evirgen S;Akyuz F;Karaca C;Besisik F;Kaymakoglu S;Ustek D;Demir K Eur Rev Med Pharmacol Sci. 2016 Mar;20(5):879-85.
OBJECTIVE: ;Cytochrome P450 2C19 (CYP2C19) polymorphisms play an important role in the metabolism of proton pump inhibitors. Rabeprazole is primarily metabolized via non-enzymatic pathways. In this study, we determined whether rabeprazole- and pantoprazole-based eradication treatments were influenced by CYP2C19 polymorphisms.;PATIENTS AND METHODS: ;A total of 200 patients infected with Helicobacter pylori were treated with either 40 mg of pantoprazole or 20 mg of rabeprazole plus 500 mg of clarithromycin, 1000 mg of amoxicillin twice daily for 2 weeks. CYP2C19 genotype status was determined by Polymerase Chain Reaction (PCR)-restriction-fragment-length polymorphism. The genotypes of cytochrome P450 2C19 were classified as homozigote extensive metabolizer (HomEM), heterozigote metabolizer (HetEM) and poor metabolizer (PM). The CYP2C19 genotype of all patients, the effectiveness of the treatment, the effect of the genotypic polymorphism on the treatment were assessed.;RESULTS: ;The frequencies of HotEM, HetEM, PM were 78%, 19.5% and 2.5%, respectively. 48% (n = 96) of the patients received treatment with rabeprazole and 52% (n = 104) with pantoprazole. The eradication rate was 64.7% for HomEM, 79.
2.Helicobacter pylori eradication therapy success regarding different treatment period based on clarithromycin or metronidazole triple-therapy regimens.
Filipec Kanizaj T;Katicic M;Skurla B;Ticak M;Plecko V;Kalenic S Helicobacter. 2009 Feb;14(1):29-35. doi: 10.1111/j.1523-5378.2009.00656.x.
BACKGROUND: ;The study compares the eradication success of standard first-line triple therapies of different durations (7, 10, and 14 days).;MATERIALS AND METHODS: ;A total of 592 naive Helicobacter pylori-positive patients were randomized to receive pantoprazole, amoxicillin, and clarithromycin or metronidazole for 14 days (PACl14 or PAM14), 10 days (PACl10 or PAM10), or 7 days (PACl7 or PAM7). H. pylori eradication was assessed by histological, microbiological, and rapid urease examination.;RESULTS: ;The intention-to-treat (ITT) and per-protocol (PP) analyses have shown no overall statistically significant differences between the eradication success of PACl and PAM treatment groups (ITT p = .308, PP p = .167). Longer treatment duration has yielded statistically significant increase in eradication success for clarithromycin (ITT p = .004; PP p = .004) and metronidazole (ITT p = .010; PP p = .034) based regimens. Namely, PACl10, PACl14, and PAM14 protocols resulted in eradication success exceeding 80% in ITT and 90% in PP analysis. Primary resistance to clarithromycin and metronidazole equals 8.2% and 32.9%, respectively. Prolonging the metronidazole-based treatment duration in patients with resistant strains resulted in statistically significant higher eradication success.
3.Enantiomeric separation of chiral sulfoxides by supercritical fluid chromatography.
Toribio L;Alonso C;del Nozal MJ;Bernal JL;Jiménez JJ J Sep Sci. 2006 Jul;29(10):1363-72.
The application of supercritical fluid chromatography (SFC) to the enantiomeric separation of several chiral sulfoxides belonging to the family of the substituted benzimidazoles, including omeprazole, lansoprazole, pantoprazole, rabeprazole, oxfendazole and ricobendazole, is presented in this work. The column employed was Chiralpak AD and the effect of different chromatographic conditions was studied. The results obtained showed that all the compounds can be enantiomerically resolved using SFC, with resolutions higher than 2 and analysis times that in most cases were lower than 10 min. Alcohol type modifiers provided the best results, with ricobendazole, oxfendazole, and omeprazole showing the highest retentions and resolutions. Study of the temperature effect revealed that, in general, the isoelution temperature was above the temperatures assayed, except in the cases of omeprazole, lansoprazole, and oxfendazole with ethanol as modifier and pantoprazole with acetonitrile. Enthalpy-entropy compensation could also be demonstrated for the retention of the first and second eluted enantiomers as well as for the selectivity, with compensation temperatures of 25 degrees C, 45 degrees C, and 83 degrees C, respectively.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Proton Pump Products


Lansoprazole sodium
(CAS: 226904-00-3)

Lansoprazole sodium is the sodium salt form of Lansoprazole. Lansoprazole, a substituted benzimidizole, is proton pump inhibitor, is a proton pump inhibitor whi...

CAS 102625-70-7 Pantoprazole

Pantoprazole
(CAS: 102625-70-7)

Pantoprazole, an irreversible protonpump inhibitor, inhibits the final step of the production ofgastric acid by binding to the sites of H+/K+ ATPase system in g...

CAS 261944-46-1 Soraprazan

Soraprazan
(CAS: 261944-46-1)

Soraprazan, also known as BY359, is a reversible, and fast-acting inhibitor of gastric H+/K+ ATPase, used as anti-secretory drug.

CAS 117976-90-6 Rabeprazole Sodium

Rabeprazole Sodium
(CAS: 117976-90-6)

The sodium salt form of Rabeprazole which is a partially reversible inhibitor of gastric proton pump and could be used in the treatment of sorts of gastrointest...

CAS 335299-59-7 Tenatoprazole sodium

Tenatoprazole sodium
(CAS: 335299-59-7)

Tenatoprazole is a novel proton pump inhibitor which is similar to the chemical structure of omeprazole, a widely used proton pump inhibitor. Tenatoprazole belo...

CAS 117976-89-3 Rabeprazole

Rabeprazole
(CAS: 117976-89-3)

Rabeprazole, a partially reversible inhibitor of gastric proton pump, could be used in the treatment of sorts of gastrointestinal disease especially peptic ulce...

Esomeprazole magnesium salt
(CAS: 1198768-91-0)

The magnesium salt form of Esomeprazole which is a proton pump inhibitor so that could be probably useful in the treatment of sorts of digestive tract diseases ...

CAS 138530-94-6 Dexlansoprazole

Dexlansoprazole
(CAS: 138530-94-6)

Dexlansoprazole is a proton pump inhibitor that is marketed by Takeda Pharmaceuticals for the treatment of erosive esophagitis and gastro-oesophageal reflux dis...

Chemical Structure

CAS 102625-70-7 Pantoprazole

Quick Inquiry

Verification code

Featured Items